SARS-CoV-2-IPV / E-MO Biology, HWGB - LARVOL DELTA

Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19) (clinicaltrials.gov) - P4; N=300; Active, not recruiting; Sponsor: E-MO Biology Inc; Recruiting ➔ Active, not recruiting; Trial completion date: Apr 2021 ➔ Jun 2022

Enrollment closed • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19) (clinicaltrials.gov) - P4; N=300; Recruiting; Sponsor: E-MO Biology Inc; N=25 ➔ 300; Trial completion date: Jan 2021 ➔ Apr 2021; Trial primary completion date: Jan 2021 ➔ Apr 2021

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases